MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- Sector Info (pharmaceuticals)
- MNC Pharma
MNC Pharma Stocks 
Here are the latest stock price details of India's top MNC Pharma stocks. For more detailed updates, read our MNC Pharma sector report and check the latest MNC Pharma sector results.
| SCRIP | BSE PRICE (Rs) | NSE PRICE (Rs) | CHART | MORE INFO |
|---|---|---|---|---|
| ABBOTT INDIA | 7,504.35 -0.14% | 7,508.00 0.06% | More Info
|
|
| GSK PHARMA | 1,393.85 0.51% | 1,402.05 1.00% | More Info
|
|
| MERCK LTD | 2,842.85 0.39% | 2,841.30 0.42% | More Info
|
|
| NIFTY 50 | Not Listed | 10,791.55 0.50% | More Info
|
|
| NOVARTIS | 741.65 0.09% | Not Listed | More Info
|
|
| PFIZER | 2,827.10 -1.10% | 2,832.00 -1.14% | More Info
|
|
| S&P BSE SENSEX | 35,929.64 0.42% | Not Listed | More Info
|
|
| SANOFI INDIA | 6,276.55 0.28% | 6,299.40 0.62% | More Info
|
BSE prices: December 13, 2018 (Close) NSE prices: December 13, 2018 (Close)
MNC Pharma Stocks Update
The NIFTY PHARMA Index was at 8,818.1 (up 0.2%). The index is down 14.4% over the last 30 days. And over the last 1 year, it has lost 6.1%.
Within the MNC Pharma sector, the top gainers were GSK PHARMA (up 0.5%) and MERCK LTD (up 0.4%). On the other hand, PFIZER (down 1.1%) and ABBOTT INDIA (down 0.1%) were among the top losers.
Meanwhile, the benchmark NIFTY 50 was at 10,791.6 (up 0.5%).
|
| |
Today's Market
Sensex Ends 150 Points Higher; Banking Stocks Witness Buying(Closing)
Indian share markets continued their momentum and ended the day on a positive note. Gains were largely seen in the banking sector, consumer durables sector and realty sector.
Related Views on News
NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)
Nov 21, 2018 | Updated on Nov 21, 2018For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)
Nov 15, 2018 | Updated on Nov 15, 2018For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)
Nov 30, 2018Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.
4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)
Dec 3, 2018Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.
Safety Beats Growth in 2018(Chart Of The Day)
Nov 30, 2018With the markets turning up, these are my top 7 stock picks.
Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)
Dec 5, 2018Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.
DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)
Dec 5, 2018PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.
More|
| |
S&P BSE HEALTHCARE
Dec 13, 2018 (Close)
S&P BSE HEALTHCARE 5-YR ANALYSIS
COMPARE COMPANY
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.